Novo Nordisk Acquires Inversago Pharma for $1.08 Billion to Expand Weight Loss Portfolio
Novo Nordisk to Acquire Inversago Pharma and Expand Weight Loss Portfolio Novo Nordisk’s Latest Acquisition Novo Nordisk announced on Thursday that it will acquire Inversago Pharma, a privately held obesity drug maker, for up to $1.08 billion. This acquisition aims to expand Novo Nordisk’s blockbuster weight loss portfolio. Capitalizing on the Weight Loss Industry Boom…